Switch theme
Sign up to access all valuation multiples
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
2017
75
Last FY Revenue $1.7M
Last FY EBITDA -$2.6M
$169M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, China SXT Pharmaceuticals achieved revenue of $1.7M and an EBITDA of -$2.6M.
China SXT Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China SXT Pharmaceuticals valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.7M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 21% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -148% | XXX | XXX | XXX |
| EBIT | XXX | -$2.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -154% | XXX | XXX | XXX |
| Net Profit | XXX | -$3.3M | XXX | XXX | XXX |
| Net Margin | XXX | -190% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, China SXT Pharmaceuticals's stock price is $2.
China SXT Pharmaceuticals has current market cap of $186M, and EV of $169M.
See China SXT Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $169M | $186M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, China SXT Pharmaceuticals has market cap of $186M and EV of $169M.
China SXT Pharmaceuticals's trades at 96.8x EV/Revenue multiple, and -65.5x EV/EBITDA.
Equity research analysts estimate China SXT Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China SXT Pharmaceuticals's P/E ratio is not available.
See valuation multiples for China SXT Pharmaceuticals and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $186M | XXX | $186M | XXX | XXX | XXX |
| EV (current) | $169M | XXX | $169M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 96.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -65.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -62.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -56.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -71.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChina SXT Pharmaceuticals's revenue per employee in the last FY averaged $23K, while opex per employee averaged $41K for the same period.
China SXT Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China SXT Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for China SXT Pharmaceuticals and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -148% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $23K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 175% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China SXT Pharmaceuticals acquired XXX companies to date.
Last acquisition by China SXT Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . China SXT Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was China SXT Pharmaceuticals founded? | China SXT Pharmaceuticals was founded in 2017. |
| Where is China SXT Pharmaceuticals headquartered? | China SXT Pharmaceuticals is headquartered in United States of America. |
| How many employees does China SXT Pharmaceuticals have? | As of today, China SXT Pharmaceuticals has 75 employees. |
| Who is the CEO of China SXT Pharmaceuticals? | China SXT Pharmaceuticals's CEO is Mr. Feng Zhou. |
| Is China SXT Pharmaceuticals publicy listed? | Yes, China SXT Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of China SXT Pharmaceuticals? | China SXT Pharmaceuticals trades under SXTC ticker. |
| When did China SXT Pharmaceuticals go public? | China SXT Pharmaceuticals went public in 2019. |
| Who are competitors of China SXT Pharmaceuticals? | Similar companies to China SXT Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of China SXT Pharmaceuticals? | China SXT Pharmaceuticals's current market cap is $186M |
| Is China SXT Pharmaceuticals profitable? | Yes, China SXT Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
